Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension Study Evaluating the Safety and Efficacy of ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults (The Encore Study)

NCT05243719 is registered in ClinicalTrials.gov with Alladapt Immunotherapeutics, Inc. as lead sponsor.

NCT NCT05243719
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05243719 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension Study Evaluating the Safety and Efficacy of ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults (The Encore Study)
Lead sponsor
Alladapt Immunotherapeutics, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
March 14, 2022
Completion date
February 27, 2024
Enrollment
45 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

food allergy